Theranostics for personalized cancer care
Empowering precision oncology
Theranostics is an innovative concept of personalized therapy that focuses on both the accurate selection of patients and providing them with targeted radioligand therapy to improve their prognosis. It refers to structurally similar diagnostic and therapeutic agents that share a molecular-specific target that involves the use of molecular imaging techniques to identify, personalize, and monitor therapy response. It makes use of pharmaceuticals, such as radioligands, to target and treat specific areas.
Theranostics in comprehensive cancer care demands precision at every step of the patient care pathway.
There is no one-size-fits-all approach to theranostics, so no matter where your institution is on its theranostics journey, we want to empower you with the tools you need to plan, implement, and expand your program to meet the demands of tomorrow.
Clinical image gallery
Molecular imaging plays a role in personalizing treatment for prostate cancer, liver cancer, neuroendocrine tumors, and thyroid cancer.
Data courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
Theranostics for prostate cancer (PSMA)
15-minute, whole-body SPECT/CT with xSPECT Quant provides high sensitivity to assess 177Lu-PSMA therapy response
The outcomes achieved by the Siemens Healthineers customers described herein were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (eg, hospital size, case mix, level of IT adoption) there can be no guarantee that others will achieve the same results.